Ayurveda market seen hitting $107.62 billion by 2035

Market Research Future projects the global Ayurveda market will grow from $24.55 billion in 2026 to $107.62 billion by 2035, driven by plant-based wellness demand, government support, and digital distribution. The report says faster regulation, clinical validation, and e-commerce are turning Ayurvedic products into a mainstream global category.

Why it matters: - The Ayurveda market is projected to nearly quadruple by 2035, pointing to a broader shift from niche traditional remedies to mainstream wellness and pharmacy channels. - Growth could reshape herbal medicine supply chains, digital health retail, and integrative care offerings across North America, Europe, and Asia-Pacific. - The report also suggests more institutional adoption, including research, payer interest, and cross-border manufacturing.

What happened: - Market Research Future forecast the global Ayurveda market will reach $107.62 billion by 2035. - The market is projected to rise from $24.55 billion in 2026, with a 17.82% CAGR from 2026 to 2035. - The market base was estimated at $20.84 billion in 2025. - The report argues the growth rate is being driven by plant-based wellness demand, regulatory support, and e-commerce expansion. - A free sample is available here.

The details: - India’s National AYUSH Mission has directed more than $580 million into traditional Indian healing infrastructure since 2020. - India’s Union Budget allocation for AYUSH rose to INR 4,408.93 crore for fiscal 2025-26. - The EU’s Traditional Herbal Medicinal Products Directive allows standardized registrations across member states. - The U.S. herbal supplement market reached $13.23 billion in 2024, based on SPINS and Nutrition Business Journal tracking data. - Amazon India launched a dedicated Ayurveda Storefront in February 2022, with support from the Ministry of AYUSH. - Tata 1mg and PharmEasy have also added dedicated herbal and Ayurvedic segments. - The NIH allocated $47 million in 2024 to integrative medicine grants that include Ayurvedic protocols. - Academic publications on panchakarma detox therapy outcomes have tripled since 2018. - CCRAS has finalized multiple international and domestic research collaborations. - Mankind Pharma acquired Upakarma Ayurveda in November 2022. - The report says the market is low concentration, with an HHI below 500 and the top five players holding about 22% to 28% of global revenue. - The report lists more than 4,000 licensed manufacturers and 780,000 registered practitioners in India. - India’s Traditional Knowledge Digital Library has documented more than 300,000 formulations.

Between the lines: - The report frames Ayurveda’s growth as a mix of consumer demand and institutional legitimacy, not just wellness branding. - E-commerce, clinical research, and regulatory standardization appear to be doing the heavy lifting by making products easier to buy, easier to verify, and easier to scale. - The segment data also shows Ayurveda is broadening beyond medicines into personal care, digestive health, and premium beauty products. - Several projections rely on forward-looking assumptions, including AI-driven personalization, insurance pilots, and broader clinical adoption.

What’s next: - The report expects AI-driven wellness platforms to influence more than 60% of Ayurvedic product selections in leading markets by 2030. - Decentralized clinical trials using wearables and at-home sample collection could make up 40% of Phase II/III precision Ayurveda trials by 2028. - US and European insurers may begin coverage pilots by 2029 if evidence on panchakarma and related protocols keeps strengthening. - The report says insurance adoption could unlock an additional $8 billion to $12 billion in revenue by 2035. - More consolidation is likely as larger companies and data-platform players seek scale through mergers, digital channels, and research-backed product lines.

The bottom line: - Ayurveda is moving from traditional practice to a global commercial category, and the next growth phase will depend on proof, regulation, and distribution as much as consumer interest.